PFS Partners’s Guardant Health GH Stock Holding History

PFS Partners’s Portfolio GH Stock Details GH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$49.5K	Hold	330	–	–	0.02%	203
2026 Q1	$30.5K	Hold	330	–	–	0.01%	241
2025 Q4	$33.7K	Hold	330	–	–	0.02%	221
2025 Q3	$20.6K	Buy	+330	New	+$18K	0.01%	266

Other funds holding GH

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

PFS Partners's GH Position: Q2 2026 in Review

PFS Partners held its Guardant Health (GH) position steady in Q2 2026 at 330 shares worth $49.5K. The position accounts for 0.02% of the portfolio, ranked #203.

PFS Partners first reported a position in GH in Q3 2025 and has held it in 4 quarters since. 598 funds tracked by Wall St. Rank hold GH as of Q2 2026.

PFS Partners held 330 shares of Guardant Health worth $49.5K as of Q2 2026.
PFS Partners left its Guardant Health share count unchanged in Q2 2026.
Guardant Health made up 0.02% of PFS Partners's portfolio in Q2 2026, its #203 holding.
PFS Partners first reported a position in Guardant Health in Q3 2025 and has held it in 4 quarters since.
598 funds tracked by Wall St. Rank held Guardant Health as of Q2 2026.

Based on PFS Partners's 13F filing for Q2 2026, filed 20 Jul 2026.